Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy

Haixia Long,Qingzhu Jia,Liuyang Wang,Wenfeng Fang,Zhongyu Wang,Tao Jiang,Fei Zhou,Zheng Jin,Jiani Huang,Li Zhou,Chunyan Hu,Xinxin Wang,Jin Zhang,Yujie Ba,Yujie Gong,Xianghua Zeng,Dong Zeng,Xingxing Su,Peter B Alexander,Li Wang,Limei Wang,Yisong Y Wan,Xiao-Fan Wang,Li Zhang,Qi-Jing Li,Bo Zhu,Peter B. Alexander,Yisong Y. Wan

DOI: https://doi.org/10.1016/j.ccell.2022.04.018

IF: 50.3

2022-06-14

Cancer Cell

Abstract:Long et al. demonstrate that erythropoiesis in tumor-carrying patients and animals is hijacked for myelopoiesis. This erythroid-to-myeloid transdifferentiation is accompanied by the stepwise enrichment of immunosuppressive machinery. EDMC intratumoral abundance and degree of anemia predict T cell exhaustion, microenvironmental suppression, and immune checkpoint inhibitor treatment resistance in multiple cohorts.

oncology,cell biology